Neurocrine Biosciences Reports Ingrezza (valbenazine) Q4 And FY23 Net Product Sales Of $500M And $1.84B, Representing YoY Growth of 25% and 29% Respectively
Portfolio Pulse from Benzinga Newsdesk
Neurocrine Biosciences announced Q4 and FY23 net product sales for Ingrezza (valbenazine) of $500M and $1.84B, showing year-over-year growth of 25% and 29% respectively.
February 07, 2024 | 12:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Neurocrine Biosciences reported significant year-over-year growth in net product sales for Ingrezza, with Q4 sales of $500M and FY23 sales of $1.84B.
The reported year-over-year growth in sales for Ingrezza directly impacts Neurocrine Biosciences' financial health and growth trajectory. Such positive earnings reports typically lead to increased investor confidence and can positively influence the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100